header logo image


Page 410«..1020..409410411412..420430..»

Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy – Endpoints News

August 22nd, 2020 3:54 pm

Salk Institute scientist and serial biotech entrepreneur Ron Evans showed new mouse work yesterday that could point to a long-sought holy grail for diabetes treatment.

The study, published in Nature,involved a new approach for islet cell transplant, a diabetes therapy where dysfunctional insulin-producing cells on the pancreas are replaced with functional ones. The treatment has been around for a while and new ones are in development, but theyve been hampered by the fact that patients will reject the cells unless they go on immuno-suppressive drugs.

But, working with iPSC stem cells and tricks from immunotherapy, Evans and his team developed what they called immune-evasive clusters of cells essentially mini pancreases. Placed into mice, these cells secreted proper amounts of insulin without coming under fire from immune cells, pointing the way toward a similar approach in humans.

Most type 1 diabetics are children and teenagers, Evans said in a statement. We hope that regenerative medicine in combination with immune shielding can make a real difference in the field by replacing damaged cells with lab-generated human islet-like cell clusters that produce normal amounts of insulin on demand.

Evans, who most recently co-founded and sold to Astellas the exercise-in-a-pill biotech Mitobridge, and his co-authors are hardly alone in this race. ViaCyte has received major backing from both private donors and the Juvenile Diabetes Research Foundation for their own stem cell-derived islet cell transplant. Flagship also launched Sigilon earlier this year with $80.3 million in Series B funding. With technology from Robert Langer, the company is developing polymers that can encase cells for transplant. A diabetes program is in the IND-enabling phase with Eli Lilly.

Four years ago, Evans and his team figured out how to make functional pancreatic beta cells for the first time, using a series of molecular switches to get them to not only produce insulin but do so in response to glucose, as normal cells do. But that still left questions about how to go from individual cells into pancreas-like clusters, and how to get those cells to avoid the immune system when transplanted.

To cluster the cells, Evans lab figured out that a protein involved in embryonic development called WNT4 could trigger the same molecular mechanisms that created the functional beta cells. Adding that protein led to the creation of 3-D clusters of cells similar to what would be seen in a humans. They called them human islet-like organoids, or HILOs.

To make those organoids, Evans and Eiji Yoshihara, a scientist in his lab, stole a trick from another field: immuno-oncology. Using short pulses of a protein called interferon gamma, Yoshihara got the cells to express PD-L1.

The PD-L1 had the opposite effect of the PD-L1 inhibitors used in cancer. Rather than making sure T cells saw a tumor, they made sure T cells didnt see the islet cells.

This is the first study to show that you can protect HILOs from the immune system without genetic manipulation, Michael Downes, an author on the paper, said. If we are able to develop this as a therapy, patients will not need to take immune-suppressing drugs.

See the article here:
Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy - Endpoints News

Read More...

Contact tracing apps may be ineffective for reducing Covid-19 spread: Study – ETHealthworld.com

August 22nd, 2020 3:54 pm

Illustration / Peter Hamlin;LONDON: Contact tracing apps are unlikely to contain the spread of Covid-19 without proper public health control measures such as physical distancing and closure of indoor spaces, according to a review of studies.

The systematic review, published in the journal Lancet Digital Health on Thursday, shows that evidence around the effectiveness of automated contact tracing systems is currently very limited.

The research suggests that large-scale manual contact tracing alongside other public health control measures -- such as physical distancing and closure of indoor spaces such as pubs -- is likely to be required in conjunction with automated approaches.

They analysed these to understand the potential impact these tools could have in controlling the Covid-19 pandemic.

"Across a number of modelling studies, we found a consistent picture that although automated contact tracing could support manual contact tracing, the systems will require large-scale uptake by the population and strict adherence to quarantine advice by contacts notified to have a significant impact on reducing transmission, said lead author Isobel Braithwaite from UCL.

In total, 4,033 papers published between January, 2000 and April, 2020 were reviewed, which allowed researchers to identify 15 papers with useful data.

The seven studies that addressed automated contact tracing directly were modelling studies that all focused on Covid-19.

Partially-automated systems may have some automated processes, for instance in determining the duration of follow-up of contacts required, but do not use proximity of smartphones as a proxy for contact with an infected person.

Analysis of automated contact tracing apps generally suggested that high population uptake of relevant apps is required alongside other control measures, while partially-automated systems often had better follow-up and slightly more timely intervention.

"None of the studies we found provided real-world evidence of their effectiveness, and to improve our understanding of how they could support manual contact tracing systems, Braithwaite said.

The review shows that, at present, there is insufficient evidence to justify reliance on automated contact tracing approaches without additional extensive public health control measures.

"We currently do not have good evidence about whether a notification from a smartphone app is as effective in breaking chains of transmission by giving advice to isolate due to contact with a case of Covid-19 when compared to advice provided by a public health contact tracer, said Robert Aldridge from UCL Institute of Health Informatics.

We urgently need to study this evidence gap and examine how automated approaches can be integrated with existing contact tracing and disease control strategies, and generate evidence on whether these new digital approaches are cost-effective and equitable," Aldridge said.

If implemented effectively and quarantine advice is adhered to appropriately, automated contact tracing may offer benefits such as reducing reliance on human recall of close contacts, which could enable identification of additional at-risk individuals, informing potentially affected people in real-time, and saving on resources, the researchers said.

"We should be mindful that automated approaches raise potential privacy and ethics concerns, and also rely on high smartphone ownership, so they may be of very limited value in some countries, Braithwaite said.

Too much reliance on automated contact tracing apps may also increase the risk of Covid-19 for vulnerable and digitally-excluded groups such as older people and people experiencing homelessness, Braithwaite added.

Read more from the original source:
Contact tracing apps may be ineffective for reducing Covid-19 spread: Study - ETHealthworld.com

Read More...

Global Impact of Covid-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market to Record Significant Revenue Growth During the Forecast…

August 22nd, 2020 3:53 pm

The Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry study now available at Grand View Report, is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix. The report also indicates a pointwise outline of market share, market size, industry partakers, and regional landscape along with statistics, diagrams, & charts elucidating various noteworthy parameters of the industry landscape.

The Chemotherapy Induced Peripheral Neuropathy Treatment Market research report offers an exhaustive analysis of this business space. The key trends that define the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market during the analysis timeframe are mentioned in the report, alongside other factors such as regional scope and regulatory outlook. Also, the document elaborates on the impact of current industry trends on key market driving factors as well as top challenges.

Request a sample Report of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market at:https://grandviewreport.com/sample/8560

Covid-19 pandemic affects most industries in the globe. Here at Grand View Report we offer you comprehensive data of related industry which will help and support your business in all possible ways.

Top Key Players Profiled in This Report: , Achelios Therapeutics Inc, Advinus Therapeutics Ltd, Apollo Endosurgery Inc, Aptinyx Inc, Asahi Kasei Pharma Corp, Can-Fite BioPharma Ltd, Celgene Corp, DermaXon LLC, Eisai, Immune Pharmaceuticals Inc, INSYS Therapeutics Inc, Kineta Inc, KPI Therapeutics Inc, Krenitsky Pharmaceuticals Inc, MAKScientific LLC, Metys Pharmaceuticals AG, Midatech Pharma US Inc, Mundipharma International Ltd, Nemus Bioscience Inc, Neurocentrx Pharma Ltd, Panacea Pharmaceuticals Inc, PeriphaGen Inc, PharmatrophiX Inc, PledPharma AB, Sova Pharmaceuticals Inc, Virobay Inc, WEX Pharmaceuticals Inc

The study also provides with a summary of the competitive spectrum as well as an in-depth assessment of the raw materials and downstream buyers.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

Our study helps to acquire the following:

Elaborating on the competitive landscape of Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

A gist of the regional scope of the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market:

Ask for Discount on Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry Market Report at:https://grandviewreport.com/discount/8560

Other information mentioned in the Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market report:

The report answers important questions that companies may have when operating in the global Chemotherapy Induced Peripheral Neuropathy TreatmentIndustry market. Some of the questions are given below:

For More Details On this Report:http://grandviewreport.com/industry-growth/Chemotherapy-Induced-Peripheral-Neuropathy-Treatment-Market-8560

See the rest here:
Global Impact of Covid-19 on Chemotherapy Induced Peripheral Neuropathy Treatment Market to Record Significant Revenue Growth During the Forecast...

Read More...

Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 – The News Brok

August 22nd, 2020 3:53 pm

Global Diabetic Neuropathy Market Report, Sales and Consumption Status and Prospects Professional Research, the report classifies the Global Diabetic Neuropathy Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

Diabetic Neuropathy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Diabetic Neuropathy market between 2020 and 2027. In terms of value, the Diabetic Neuropathy industry is expected to register a steady CAGR during the forecast period.

To learn more about this report, request a sample copy*

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Get Free Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

The key players profiled in this report include: Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Global (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion ofDiabetic Neuropathy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographic

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Diabetic Neuropathy market

Table of Contents

Report Overview: It includes the Diabetic Neuropathy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Diabetic Neuropathy market trends and shares, market size analysis by region and analysis of Global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Diabetic Neuropathy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in theDiabetic Neuropathy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

The research study can answer the following Key questions:

What will be the progress rate of the Diabetic Neuropathy Market for the conjecture period, 2020-2027?What are the prominent factors driving the Diabetic Neuropathy Market across different regions?Who are the major vendors dominating the Diabetic Neuropathy industry and what are their winning strategies?What will be the market scope for the estimated period?What are the major trends shaping the expansion of the industry in the coming years?What are the challenges faced by the Diabetic Neuropathy Market?

Major Highlights of TOC:

Chapter One: GlobalDiabetic Neuropathy Market Industry Overview

1.1Diabetic Neuropathy Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2Diabetic Neuropathy Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: GlobalDiabetic Neuropathy Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Diabetic Neuropathy Market Size by Demand

2.3 Global Diabetic Neuropathy Market Forecast by Demand

Chapter Three: GlobalDiabetic Neuropathy Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2Diabetic Neuropathy Market Size by Type

3.3Diabetic Neuropathy Market Forecast by Type

Chapter Four: Major Region ofDiabetic Neuropathy Market

4.1 Global Diabetic Neuropathy Sales

4.2 Global Diabetic Neuropathy Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

**Be Safe and Stay Home**

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.ShahPhone: US +1-206-701-6702/UK +44-020 8133 4027[emailprotected]

Continued here:
Diabetic Neuropathy Market :How The Will Perform In Upcoming Years Based On Size, Share And Demand In Major Regions | 2020-2026 - The News Brok

Read More...

Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 – Owned

August 22nd, 2020 3:53 pm

The Cardiac Autonomic Neuropathy Treatment Market globally is a standout amongst the most emergent and astoundingly approved sectors. This worldwide market has been developing at a higher pace with the development of imaginative frameworks and a developing end-client tendency.

Given the debilitating impact of COVID-19 (Coronavirus) on the Cardiac Autonomic Neuropathy Treatment market, companies are vying opportunities to stay afloat in the market landscape. Gain access to our latest research analysis on COVID-19 associated with the Cardiac Autonomic Neuropathy Treatment market and understand how market players are adopting new strategies to mitigate the impact of the pandemic.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/14518

The worldwide Cardiac Autonomic Neuropathy Treatment market is an enlarging field for top market players,

key players in Cardiac autonomic neuropathy treatment market are Pfizer Inc., Roche Holding AG, Novartis, Amgen Inc., Privi Pharma Limited, Silverline Chemicals Limited, Anthem Biopharma, Praxis Pharmaceutical.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

The regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/14518

This Cardiac Autonomic Neuropathy Treatment report begins with a basic overview of the market. The analysis highlights the opportunity and Cardiac Autonomic Neuropathy Treatment industry trends that are impacted the market that is global. Players around various regions and analysis of each industry dimensions are covered under this report. The analysis also contains a crucial Cardiac Autonomic Neuropathy Treatment insight regarding the things which are driving and affecting the earnings of the market. The Cardiac Autonomic Neuropathy Treatment report comprises sections together side landscape which clarifies actions such as venture and acquisitions and mergers.

The Report offers SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, request, limit, supply, and market development rate and figure.

Quantifiable data:-

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America, Europe, China, Japan, Southeast Asia, India

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/14518

Research objectives and Reason to procure this report:-

Finally, the global Cardiac Autonomic Neuropathy Treatment market provides a total research decision and also sector feasibility of investment in new projects will be assessed. Cardiac Autonomic Neuropathy Treatment industry is a source of means and guidance for organizations and individuals interested in their market earnings.

Excerpt from:
Cardiac Autonomic Neuropathy Treatment Market Is Expected To Experience An Impressive CAGR Growth Of XX% Through 2017 2025 - Owned

Read More...

Healthy heart linked with low risk of eye disease and sight loss – Brinkwire

August 22nd, 2020 3:52 pm

Age-old advice on how to look after your heart also applies to staving off eye disease and sight loss, a new study claims.

US researchers have linked good cardiovascular health from a healthy diet, regular exercise and not smoking with lower odds for ocular diseases.

This includes diabetic retinopathy, a condition caused by high blood sugar levels damaging the retina that can lead to blindness and cataracts, when the lens develops cloudy patches.

Earlier studies have observed associations between eye diseases and individual lifestyle factors such as smoking, obesity or hypertension, said study author Duke Appiah at Texas Tech University Health Sciences Center in the US.

It is known that these metrics of ideal cardiovascular health do not work alone and may interact additively to result in diseases.

However, prior to our research, no other studies have comprehensively evaluated the association of all of the metrics of ideal cardiovascular health with ocular diseases.

Globally, about 2.2 billion people suffer from ocular diseases leading to vision impairment or blindness, but aroundhalf of these cases could have been prevented.

The leading causes of vision impairment or blindness are diabetic retinopathy, cataract, age-related macular degeneration and glaucoma.

Most ocular diseases show few symptoms at early stages and many people may not seek medical care despite readily available treatments.

The aim of this study was to evaluate the relation between the American Heart Associations prescription prescription for health metric, known as Lifes Simple Seven (LS7), and the occurrence of ocular diseases

LS7 is based on the status of seven cardiovascular disease risk factors not smoking, regular physical activity, healthy diet, maintaining normal weight and controlling cholesterol, blood pressure and blood glucose levels.

Following healthy lifestyle and behaviour habits can all contribute to good cardiovascular health as assessed by LS7.

Investigators evaluated data from 6,118 adults aged 40 or more years old who took part in the 2005-2008 National Health and Nutrition Examination Survey.

The average age of participants was 57 years old, 53 percent of whom were women.

Scores were summed for a maximum of 14, which indicated the most ideal level of cardiovascular health.

A one-unit increase in LS7 scores was associated with reduced odds for age-related macular degeneration by 95 per cent, diabetic retinopathy (68 per cent), cataracts (94 per cent) and glaucoma (94 per cent).

Individuals with optimal cardiovascular health had 97 percent lower odds for diabetic retinopathy compared to individuals with inadequate cardiovascular health.

Overall, we believe that primary prevention and early detection approaches of ocular diseases are important, considering that over half of all deaths from ocular diseases and cardiovascular diseases are known to be preventable, said co-investigator Noah De La Cruz at Texas Tech University Health Sciences Center.

Since there is a overlap of the risk factors for ocular diseases and cardiovascular disease, the investigators recommended that screening for ocular diseases be incorporated into existing screenings for cardiovascular diseases.

We hope that our study findings will encourage adherence to healthy lifestyles in order to prevent these age-related diseases while also leading to increased collaborations between cardiologists, optometrists, and ophthalmologists in order to better prevent cardiovascular and ocular diseases, said Dr Appiah.

The study has been published in The American Journal of Medicine.

Visit link:
Healthy heart linked with low risk of eye disease and sight loss - Brinkwire

Read More...

Man fears he could be left homeless as well as blind in one eye after ‘attack’ in Lincoln – LincolnshireLive

August 22nd, 2020 3:52 pm

A man who has been told he may be permanently blinded in one eye after he was struck with glass in Lincoln fears he may also be left homeless.

Kane Lilleyman suffered a serious injury to his eye after he was allegedly attacked in Baggholme Road close to the junction with Croft Street in the Monks Road area at around 11pm on July 28.

And if the thought of never regaining his vision in one eye wasnt enough to comprehend, the 29-year-old is now seriously concerned that he could soon be without a roof over his head.

Mr Lilleyman owns and lives on a houseboat, but is what he calls a continuous cruiser meaning he has to keep moving the boat because he doesnt have a place to permanently moor the vessel.

However, the loss of his sight means he no longer feels able to move the boat safely and it is has also meant he has had to give up his job of jewellery making.

As a result of not moving the boat, he is infringing the terms of his boating licence and because he can no longer do his job, he doesnt have the income to be able to fund the money needed for a permanent mooring.

He told Lincolnshire Live : I am too scared to move it [the boat] because I cant tell how far the bank is from my boat, so when it comes to parking I cant tell if Im close enough to jump off or if I am too close to risk sinking via crashing.

I could face losing my boat because Ill be breaching the terms of my licence and now that Ive lost all forms of my income, I cannot afford to get a home registered mooring for the boat.

I am stuck in an extremely anxious catch 22 position and I cant see any way out of this mess.

Mr Lilleyman says it is hard not to get down as his injury has completely changed his life.

He said: I am depressed and very anxious because I am unable to move my houseboat and I have to move it by law to keep in accordance with my licence.

I am unable to continue with my jewellery making because I have no depth perception.

I cant ride my motorcycle anymore either because it is my traffic side that has been damaged.

On the whole I am pretty depressed. This has ruined most aspects of my life.

Friends have stepped in to help and have set up a Gofundme page to raise the money needed to pay the licence fees and avoid the boat being confiscated as well as then the funds for a permanent mooring.

Mr Lilleyman says he is praying the situation can be sorted as he cant bear the thought of having to give up his dream life on the water.

He said: If I cant get a permanent mooring, Ill be forced to sell the boat.

I cant face living on land. Ive been here for eight years and the water means absolutely everything to me.

Police are investigating the incident that led to Mr Lilleymans injury.

A man has been arrested on suspicion of GBH with intent but has been released pending further investigation.

A force spokesperson said: A 29-year-oldmanwas struck by a glass on Baggholme Road at the junction with Croft Street at 11pm on July 28.

The victim sustained an injury to his eye and it is thought he will not regain his sight.

This is an active police investigation and a 19-year-oldmanwas arrested. He has since been released under investigation.

Any witnesses to this incident should call 101 quoting incident 513 of July 28. To make an anonymous report, please contact CrimeStoppers.

To view the Gofundme page click here

Continue reading here:
Man fears he could be left homeless as well as blind in one eye after 'attack' in Lincoln - LincolnshireLive

Read More...

Why we are suffering more from eye strain, and how to help prevent it – Clacton and Frinton Gazette

August 22nd, 2020 3:52 pm

AN opticians is advising residents to look after their eyesight as a socially distanced work and social life means more time spent looking at screens.

Scrivens Opticians and Hearing Care, in Dovercourt, is encouraging locals to get their eyes tested after 57 per cent of people it surveyed said eye strain has been a side effect from living a virtual life during the coronavirus pandemic.

The study - carried out by OnePoll - also found many people aged 55 and over needed to re-evaluate their approach to looking after their vision.

Results showed just a fifth of those in this age group were concerned about the possible side effects of blue light on their vision - compared to half of those aged 18 to 24.

Blue light is a colour in the visible light spectrum that can be seen by human eyes - it is all around us.

The light produces higher amounts of energy and can cause eye strain, physical and mental fatigue and headaches for prolonged use of electronic devices or computers.

Claire Lethbridge, branch manager, said: As we are spending much more time using screens to communicate with colleagues, friends and family, the strain on our eyes is intense, so its vital that we give as much priority to booking an eye test as we do to taking up half price meal offers.

The same study revealed that half of the 2,000 people polled are apprehensive about booking an appointment in the wake of the pandemic.

Ms Lethbridge added: We have taken every possible precaution to make sure our store is safe for customers and for staff too.

Its so important that we take care of our eyesight and go for regular checks every two years, as they are the window to our general health too, as an eye test can detect so much more than a deterioration in our vision.

Tips for avoiding eye strain:

View post:
Why we are suffering more from eye strain, and how to help prevent it - Clacton and Frinton Gazette

Read More...

Candle Lit Tour and New Outdoor Exhibits Coming to the Baldwin Home Museum – Maui Time

August 22nd, 2020 3:51 pm

The new sports exhibit shows off some of Lahainas Pioneer Mill era sports teams.

Come take a step back into Lahainas past as Candle Lit Tours return to the Baldwin Home Museum starting Friday, Sept. 4 from 5 8 pm, alongside a new, free Pioneer Mill era sports exhibit. The tours and exhibits will be held weekly in conjunction with Friday Night is Art Night.

The Candle Lit Tour explores the fully furnished 19thcentury Baldwin Home which will be illuminated by dozens of candles. Tours are $5 per person with children 12 and under free. Each 20 minute tour is limited to 5 people. Signups will be taken on site. Docents will walk each group through the home, and once they are back outside, questions will be taken. The docents of the popular tour are excited for a return to educating the public, and invite the community to take a step back into time.

A free exhibit featuring photographs of a variety of sports teams from the Pioneer Mill era will be on display on the Baldwin Home lawn. The exhibit shows off the many memories of youth, club and community sports from the 1930s to the 1970s.

The public is invited to stroll through Historic Lahaina Town for the festive Friday Night is Art Night. Visitwww.LahainaRestoration.org for a list of participating galleries.

In conformance with Maui County regulations, masks must be worn on the candle lit tour and while looking at the outdoor exhibits. Single use masks, and hand sanitizer will be available on site and social distancing will be enforced. Please be conscious of the safety and comfort of yourself and others when attending.

Contactevents@lahainarestoration.orgfor more information

Press Release and Image courtesy Lahaina Restoration Foundation

comments

Read the original post:
Candle Lit Tour and New Outdoor Exhibits Coming to the Baldwin Home Museum - Maui Time

Read More...

Deals Under the Radar: These Are the Israeli Tech Companies Already Operating in the UAE – Algemeiner

August 22nd, 2020 3:51 pm

A general view of ADNOC headquarters in Abu Dhabi, United Arab Emirates May 29, 2019. Photo: REUTERS/Christopher Pike/File Photo.

CTech Im very active on LinkedIn, I have tens of thousands of contacts and I receive around 10 new requests a day, but something weird happened last Friday. I was swamped with new follower requests. I thought my account was hacked, but when I began looking through the names and the accounts analytics I saw that they were all businessmen and senior executives from insurance companies in the United Arab Emirates, Yariv Yanay, Director of Business Development and Innovation at Hachshara Insurance Company, told Calcalist.

Yanay is one of the founders of the go Digital Insurance application developed by Hachshara for digital car insurance. I approved all the requests and already set Zoom meetings with them. They ask serious questions that show that they know what they need from us. A representative from a big insurance company there asked me a very specific question about one of our developments in UBI (usage-based insurance) while someone else was interested in learning about dealing with claims digitally, and another inquired if the product suits a B2C market. It was apparent that they had done their homework.

Israel has become an insurtech powerhouse in recent years, even though local consumers arent aware of the services being offered by many of the companies.

Right now, I feel like they are checking us out because they have heard that Israel is an insurtech superpower, noted Yanay. The potential isnt just in the possible sale of products to the UAE, but that this can also lay the infrastructure for entering the rest of the Arab world and places like Jordan and Egypt. I take part in many international conferences and until now it was very obvious we were outcasts.

August 22, 2020 10:39 am

By complete coincidence, Yarivs brother, the CEO and President of biomed company Pluristem, announced on Monday that the regenerative medicine company developing a platform of novel biological therapeutic products has signed a non-binding Memorandum of Understanding (MOU) with the UAE-based Abu Dhabi Stem Cells Center (ADSCC), a specialist healthcare center focused on cell therapy and regenerative medicine.

Alongside insurtech and biomedicine, the fintech sector has also generated plenty of interest in the UAE. The Israeli fintech sector, which includes 530 startups, attracted record funding of $2 billion during 2019. This looks like a match made in heaven, said Shmulik Ben-Tovim, president of the Fintech Community of Israel. While Israel is regarded as a tech powerhouse, but an undeveloped financial center, in Dubai there is the exact opposite situation. Israeli fintech companies will literally be entering a desert.

Israel nowadays is mainly known in the Gulf states for its aesthetics medical innovation as Dubai and Abu Dhabi have a young and rich population, noted Adi Nov, deputy manager at ICIC-Israel Credit Insurance Company. Another strong sector is agtech, specifically irrigation technology. There is also business in the plastic industry and some fashion, mainly swimwear and underwear.

According to Paris-based insurance company Euler Hermes, which holds shares in ICIC, Israels areas of expertise are similar to those of the US which is the third-largest exporter to the UAE after China and India and is responsible for 10% of the imports in the weapons and tech sectors.

Israels tech companies werent waiting around for Donald Trumps announcement that Israel and the UAE had agreed to normalize ties, with many companies doing business in the region for several years. Most of them do so via a local distributor, but companies like Cybereason, which is based out of the US, have offices in the UAE.

The UAE is a very special and significant market, said Shai Horovitz, Chief Revenue Officer at Cybereason. The leading investor in Cybereason is the Vision Fund, with half of its $100 billion under management coming in from the Persian Gulf and Saudi Arabia. As a result, the Israeli cyber company has relationships in the region dating back many years.

There are several Israeli cybersecurity companies currently operating successfully in the UAE, including Check Point, which states on its website that it has representation in Dubai; CyberArk, which works with a local distributor; and IntSights, which has significant sales in the region.

There is a clear need for cybersecurity products due to geopolitical reasons. The Emirates encounter the same threats that our western clients are facing. The same actors that threaten large financial institutions and government agencies in Europe and the US are also acting against the UAEs interests, explained Horovitz.

Guy Nizan, co-founder and CEO of IntSights, said that Israeli tech is received very well in the region. It is an advantage because the client recognizes Israeli tech as a brand. Moreover, they understand the importance of security and are willing to invest a lot in the sector.

And it isnt just Israeli cybersecurity that is prospering in Dubai. There are several other Israeli tech companies that have made a name for themselves, including Cato Networks, whose core product is a cloud service and operates a server farm in Dubai. Israeli giant Monday.com has also become well known in the UAE over the past three years and is partnering with several companies in the region.

We have over 700 clients in the Persian Gulf and over the last year the company increased its sales in the region by 300% and is planning on reaching sales of $5 million by the end of 2021, said Barak Zigdon, partnerships and global resellers manager at Monday.com. Software company JFron is also selling to clients in the UAE.

One sector with great potential in the area is agtech, mainly due to the dry climate in both Israel and the UAE.

We have been talking to different actors in the UAE about promoting desert agriculture projects, said Or Haviv, partner and head of ventures at Arieli Capital. There is no done deal, but we were already discussing it prior to last weeks announcement. The UAE wants to learn how to do agriculture in the desert and gain produce which is at the level of that grown in Israel. There is a plan to send a delegation from the UAE to Israel so that they can undergo training at Ramat Negev.

Alan Feld, co-founder and managing partner at Vintage Investment Partners, believes that the UAE is open to investing in Israeli tech in addition to purchasing its products. I believe that we will very soon see investments in VCs and Israeli companies. They have a VC industry and they also want us to invest in their companies.

The entire region is a desert and in the middle of it they built an amazing airport and one of the best tourism systems Ive seen, added Feld, who was in the UAE in February. They want to diversify their sources of income and not be so dependent on the price of oil. They see themselves as a regional technology center and Israel is a good source of technology for them.

Boaz Dinte, managing general partner at Qumra Capital, added: Over the past two years we have received more and more approaches from people in the region who are interested in investing in Israeli funds and Israel in general. From a personal standpoint, I was a little wary as I didnt know what the consequences would be for the fund if we received money from the Gulf. I was uncertain what it would mean and if it would put constraints on the fund, but now it has clearly become legitimate.

Read the original:
Deals Under the Radar: These Are the Israeli Tech Companies Already Operating in the UAE - Algemeiner

Read More...

Book Review: What Can India’s Embrace of Nanotech Tell Us About India’s Science? – The Wire Science

August 21st, 2020 11:59 am

A glass nanoparticle suspended in an optical cavity. Photo: uclmaps/Flickr, CC BY 2.0.

Nanotechnology may not be a familiar term to many although nanotechnology-based products are available in the market and many consumers use them. Thanks to Nano Mission, an initiative funded by the Government of India through the Department of Science and Technology from May 2007, India has made great strides in nanosciences and engineering.

In this regard, Nanoscale, a new book by Pankaj Sekhsaria, a policy researcher at the Centre for Technology Alternatives for Rural Areas, IIT Bombay, doesnt eulogise the technology and its achievements nor does it criticise them and their deployment and risks.

Instead, Sekhsaria takes an atypical tack to set out what is possible, offering us new ways to conceive of and evaluate research. Through four case studies, he attempts to understand the links between science, technology and society at different sites and at different scales as if to ensure we are aware of what all is possible before we embark on our respective critical journeys. They are:

1. Developing a cutting-edge microscope at a university in Pune, despite severe constraints

2. Using nanotechnology to validate some components of a traditional Ayurvedic preparation

3. The failure of an innovative product a nano-silver-coated ceramic candle used to purify water in households

4. Nanotechnology-based treatment protocols for retinoblastoma, a cancer that affects children

The first case study concerns the construction of a scanning tunnelling microscope by C.V. Dharmadhikari at the University of Pune, using a variety of materials, including nanoparticles. Sekhsaria describes how Dharmadhikari built this sophisticated device from scratch, indigenously, and which he and his team now use for their research.

With this in mind, Sekhsaria invokes the concept of jugaad and the culture of innovation in laboratories around India. However, Eric von Hippels user innovation theory offers a better explanation: that more innovation is driven by intermediate or end users, at the site of consumption, which is then integrated by suppliers. In this case, Dharmadhikari is both a user and an innovator: he first developed the instrument and then, in the course of using it, continued to make minor modifications to better suit his and his peers purposes.

In fact, this would be true of most scientific instruments which are constantly attended to by a community of user-innovators of PhD students, postdoctoral researchers and investigators. As a result, in an ecosystem where resources are scarce and grants and funds are constantly shadowed by uncertainty, such DIY endeavours contribute more innovation and help adapt sophisticated technologies for more local conditions including nanotechnology.

Sekhsaria subsequently describes the fate of Dharmadhikari et als scanning tunnelling microscope, and compares it to that of similar innovations elsewhere in India. However, he stops short of discussing the range, utility and novelty of such instruments and how they have enabled Indian scientists to pursue science despite their constraints. Nor is there mention of how common such solutions are common across disciplines and institutions. Of course, user innovation can occur even when new instruments are acquired but if building instruments from scratch is very widely practised, it deserves a fuller study, as an important dimension of doing science in India.

The second case study concerns the use of nanotechnological tools to validate the components of a traditional Ayurvedic preparation, called bhasmas, and related work at the Centre for Nanobioscience, Agharkar Research Institute, Pune. Using the studies of Rinku D. Umrani, Sekhsaria highlights how the dialog between modern science (nanotechnology) and traditional medicine (Ayurveda) is necessary, although there are skeptics on both sides.

While the usefulness of traditional medicine is well known and accepted, it is often debunked as unscientific or considered to be scientifically unprovable. But a dialog could help better understand each system from the other systems perspective, paving the way for potentially fruitful collaborations.

With the specific example of bhasmas, Sekhsaria focuses the discussion onto the challenge of checking if Ayurveda can provide an alternative way to manage diabetes. Umranis work suggests that the mechanisms of action of some Ayurvedic preparations, including bhasmas, involve reactions involving nanoparticles. But instead of limiting himself to a yes/no answer, Sekhsaria argues that validation is necessary but a dialog as equals is more important to facilitate further research that, by extension, the introduction of radical new technologies brings with it radical new opportunities to improve the way we organise and conduct research.

Also read: Why Elon Musk Isnt Right About Nanotechnology Being BS

The third case study highlights how an innovation perceived to be locally useful to provide good quality drinking water at the household level using nanosilver-coated candles failed in the market. Researchers at the International Advanced Research Centre for Powder Metallurgy and New Materials (ARCI), Hyderabad, had developed these devices, essentially ceramic candles coated with nanoparticles of silver that could filter out some bacterial species from water.

But for the fact that they were simple to use, required less maintenance and were locally produced, they flopped at the market because they rested on the products uniqueness instead of adjusting for consumer behaviour and aspirations. The ceramic candle platform itself was becoming obsolete as a water purification technology, and newer entrants, ranging from advanced filters to ultraviolet and reverse-osmosis systems, all of which trapped more than bacteria, heightened buyers expectations.

Nonetheless, the candles were still useful, especially in low-cost settings. So Sekhsaria contends that such products shouldnt have been left at the mercy of market forces and that the government should have stepped in with subsidies. In fact, he challenges the idea that nanosilver-coated candles are obsolete per se, and argues that obsolescence is linked to infinite demands and consumption and that ARCI might have had more success if it had involved end-users during the product development process. According to him, there is also scope to recalibrate, renegotiate and revive the product, especially if were willing to learn from our mistakes.

The fourth case study is on treating retinoblastoma in female children. While nanotechnology is expected to offer better solutions like using gold-based nanoparticles to destroy cancer cells in a photothermal process the grim reality is that in some cases, parents prefer not to treat the child and let her die. This is because when children afflicted with retinoblastoma are not treated on time, they may lose eyesight and sometimes even their lives. In this regard, Sekhsaria spotlights how clinicians often talk to these childrens parents as if they are activists, and attempt to educate parents.

There is hardly any categorised data on retinoblastoma in India and how different sections of society have responded to it. It is true that technology is no panacea and the social complexities have to be taken into account but the complexity cant be reduced to that of only discrimination.

Sekhsaria discusses how girls and women are discriminated against, and how some parents choose to ignore new technologies that offer better treatment in favour of letting them die. However, his foundation is almost entirely anecdotal, based on discussions he had in two institutions in Hyderabad and Chennai. His analysis would have been enriched by including examples from more institutions, even if only in these cities, and could have fortified Sekhsarias arguments.

As such, the reader is unable to generalise from his examples as to the fraction of parents in the country who decide thus and why, nor whether the parents of male children behave the same way. Moreover, Sekhsaria discusses only those cases where parents didnt treat the child even if they had the option to do so, or accessed treatment when the retinoblastoma had entered the later stages.

Instead, the discussion could have covered the class and access to treatment dimensions. Unless we know how different sections of society respond to all the options available to them, the books view remains one-dimensional and unable to help us understand the technology-society interface. Nanotechnological solutions are not yet in vogue and are years away from widespread adoption. And even if nanotechnology has to have a positive impact, its success depends on the solutions affordability, accessibility and the decisions of parents who need to decide what is best for their children and themselves.

In fact, overall, Nanoscale often doesnt go far enough to flesh out the stories it uses to make its point about the unique prevalence of nanotechnologies across four very different slices of society, as if the book is attempting to anticipate the nanos outsized impact on society, and even social relations, in future.

Currently, India publishes the third-highest number of research papers on nanotechnology in the world. Nanotechnologies themselves have applications in sectors ranging from agriculture to textiles, from medicine to construction materials. For example, nano-fertilisers can help increase the efficiency with which plants use nutrients in the soil and help reduce nutrient run-off. Researchers have also used precepts of nanotechnology to improve hydrogen-based renewable energy technologies.

Also read: Why India Needs Nanotechnology Regulation Before it is Too Late

In this regard, Nanoscale provides a new perspective on nanotechnology in India and asks important questions about the corresponding science, technology and policies of innovation. Sekhsaria also successfully subverts conventional wisdom on innovation and attempts to link jugaad with sophistication, calls for dialog between modern science and traditional medicine, and highlights how the market can destroy innovations even as it patronises more expensive technology.

As such, Sekhsarias reluctance to pronounce verdicts works to the books advantage because, by highlighting the gap between traditional ideas of innovation in laboratories and the ground reality, he is able to contend that we can utilise nanotechnologies to a fuller extent by applying them to areas where there is a contest of paradigms or worldviews.

Krishna Ravi Srinivas works at Research and Information Systems for Developing Countries, a policy research think-tank. The views expressed here are the authors own.

See the article here:
Book Review: What Can India's Embrace of Nanotech Tell Us About India's Science? - The Wire Science

Read More...

Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 – The News Brok

August 21st, 2020 11:59 am

The Healthcare Nanotechnology (Nanomedicine) market report 2020-2026 provides in-depth study of market competitive situation, product scope, market overview, opportunities, driving force and market risks. Profile the Top Key Players of Healthcare Nanotechnology (Nanomedicine), with sales, revenue and global market share of Healthcare Nanotechnology (Nanomedicine) are analyzed emphatically by landscape contrast and speak to info. Upstream raw materials and instrumentation and downstream demand analysis is additionally administrated. The Healthcare Nanotechnology (Nanomedicine) market business development trends and selling channels square measure analyzed. From a global perspective, It also represents overall industry size by analyzing qualitative insights and historical data.

Key players operating in the global Healthcare Nanotechnology (Nanomedicine) market includes : Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith&Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International, and among others.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Healthcare Nanotechnology (Nanomedicine) Market @https://www.researchmoz.us/enquiry.php?type=S&repid2041239

Key Target Audience of the Healthcare Nanotechnology (Nanomedicine) market:

Scope of Healthcare Nanotechnology (Nanomedicine) Market:

The global Healthcare Nanotechnology (Nanomedicine) market is valued at million US$ in 2019 and will reach million US$ by the end of 2026, growing at a CAGR of during 2020-2026. The objectives of this study are to define, segment, and project the size of the Healthcare Nanotechnology (Nanomedicine) market based on company, product type, application and key regions.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Healthcare Nanotechnology (Nanomedicine) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Healthcare Nanotechnology (Nanomedicine) market.

The report offers an exhaustive geographical analysis of the global Healthcare Nanotechnology (Nanomedicine) market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The end users/applications and product categories analysis:

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate foreach application.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid2041239

Healthcare Nanotechnology (Nanomedicine) Market The Regional analysis covers:

Key Findings & Data Available in Healthcare Nanotechnology (Nanomedicine) Market Report:

And Many More.

Get Discount on Healthcare Nanotechnology (Nanomedicine) Market Report :https://www.researchmoz.us/enquiry.php?type=D&repid2041239

Contact Us:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email: [emailprotected]Follow us on LinkedIn @ http://bit.ly/2RtaFUo

Follow me on : https://marketnews-24.blogspot.com/

Read more:
Healthcare Nanotechnology (Nanomedicine) Market Analysis, Key Players, Industry Segments And Forecast To 2026 - The News Brok

Read More...

Global Nanotechnology Drug Delivery Market : Industry Analysis and Forecast (2019-2026): By Technology, Application and Region. – Good Night, Good…

August 21st, 2020 11:59 am

Global Nanotechnology Drug Delivery Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ 98.2 Bn by 2026, at a XX% CAGR of around during a forecast period.

Various novel technologies for developing effective drug delivery systems came into existence among which nanotechnology platforms for achieving targeted drug delivery are gaining prominence nowadays. Research in the medical field includes the development of drug nanoparticles, polymeric and inorganic biodegradable nano-carriers for drug delivery, and surface engineering of carrier molecules.

The report contains a detailed list of factors that will drive and restrain the growth of the Nanotechnology Drug Delivery Market. Such as, rapidly expanding areas of research and development to develop novel nano-medicine are expected to drive the nanotechnology drug delivery market growth in the future. Additionally, one of the major factors assisting market growth is the growing prevalence of infectious diseases and cancer, developing nanotechnology research, and increasing demand for novel drug delivery systems. However, high cost coupled with stringent regulatory scenario hinders the market growth to some extent.

Nanoparticles are expected to account for the largest XX% market share by 2026. The segment dominated the market as key nanoparticles like gold nanoparticles, dendrimers, and fullerenes are used in pharmaceutical drug delivery.The report offers a brief analysis of the major regions in the global nanotechnology drug delivery market, namely, APAC, Europe, North America, South America, and the Middle East & Africa. North America dominated the nanotechnology drug delivery market in 2018, because of high medical reimbursement facilities, and technological advancement. The APAC is projected to have the fastest growth, owing to a rapidly increasing population, an increase in consumer awareness, favorable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing economies such as China, and India in this region.

Nanotechnology drug delivery market report gives a competitive analysis of the individual standing of the companies against the global landscape of the medical industry. The forecast also provides the estimated trends in demand for the global market and their impact on the sizes of these companies to help the reader curate profitable business strategies. Such as Pfizer, Inc., AstraZeneca and Amgen signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the upcoming future.

The objective of the report is to present comprehensive analysis of Global Nanotechnology Drug Delivery Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Nanotechnology Drug Delivery Market dynamics, structure by analyzing the market segments, and project the Global Nanotechnology Drug Delivery Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Nanotechnology Drug Delivery Market make the report investors guide.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.Scope of the Global Nanotechnology Drug Delivery Market

Global Nanotechnology Drug Delivery Market, by Technology

Nanocrystals Nanoparticleso Dendrimerso Gold Nanoparticleso Dendrimerso Fullereneso Others Liposomes Micelles Nanotubes OthersGlobal Nanotechnology Drug Delivery Market, by Application

Neurology Oncology Cardiovascular/Physiology Anti-inflammatory/Immunology Anti-infective OthersGlobal Nanotechnology Drug Delivery Market, by Region

North America Asia Pacific Europe Middle East & Africa South AmericaKey players operating in the Global Nanotechnology Drug Delivery Market

Johnson & Johnson Merck & Co Roche Bayer Novartis Pharmaceuticals Pfizer AstraZeneca Amgen Celgene Corporation Angiotech Pharmaceuticals Capsulution Pharma AlphaRx Inc. Calando Pharmaceuticals Copernicus Therapeutics Elan Corporation Nanotherapeutics PAR Pharmaceutica Taiwan Liposome Co. AbbVie, Inc Amgen, Inc

Global Nanotechnology Drug Delivery Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/39035About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comWebsite:www.maximizemarketresearch.com

See more here:
Global Nanotechnology Drug Delivery Market : Industry Analysis and Forecast (2019-2026): By Technology, Application and Region. - Good Night, Good...

Read More...

Nanotechnology in Medical Market 2020 Explain What is the current size of the market? And key players analysis: Roche, Mitsui Chemicals, Camurus,…

August 21st, 2020 11:59 am

A complete research offering of comprehensive analysis of the market share, size, recent developments, and trends can be availed in this latest report by Big Market Research.

As per the report, theGlobal Nanotechnology in Medical Marketis anticipated to witness significant growth during the forecast period from 2020to 2025.

The report provides brief summary and detailed insights of the market by collecting data from the industry experts and several prevalent in the market. Besides this, the report offers a detailed analysis of geographical areas and describes the competitive scenario to assist investor, prominent players, and new entrants to obtain a major share of the global Nanotechnology in Medical market.

Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement. For more connect with us at [emailprotected] or call toll free: +1-800-910-6452

Request a sample of this premium research:https://www.bigmarketresearch.com/request-sample/3962053?utm_source=PF&utm_medium=ANIL

The report presents a summary of each market segment such as type, end-user, applications, and region. With the help of pie charts, graphs, comparison tables, and progress charts a complete overview of the market share, size, and revenue, and growth patterns areaccessible in the report.

Additionally, an outline of each market segments such as end user, product type, application, and region are offered in the report.The market across various regions is analyzed in the report which includes North America, Europe, Asia-Pacific, and LAMEA.The report explains future trends and growth opportunities in every region. These insights help in understanding the global trends in the market and form strategies to be implemented in the future. Moreover, the research report profiles some of the leading companies in the global Nanotechnology in Medical industry. It mentions their strategic initiatives and offers a brief about their business. Some of the players profiled in the global Nanotechnology in Medical market include:

Key players in the Nanotechnology in Medical covers :RocheMitsui ChemicalsCamurusMerckCelgeneCytimmuneAmgenAccessPfizerSmith and NephewNovartisDentsply International3M

Analysts have also stated the research and development activities of these companies and provided complete information about their existing products and services. Additionally, the report offers a superior view over different factors driving or constraining the development of the market.

The Nanotechnology in Medical can be split based on product types, major applications, and important countries as follows:

The basis of applications, the Nanotechnology in Medical from 2015 to 2025 covers:HospitalsClinicsOthers

The basis of types, the Nanotechnology in Medical from 2015 to 2025 is primarily split into:Nano MedicineNano DiagnosisOther

Request a discount on standard prices of this premium research:https://www.bigmarketresearch.com/request-for-discount/3962053?utm_source=PF&utm_medium=ANIL

The report clearly shows that the Nanotechnology in Medical industry has achieved remarkable progress since 2025 with numerous significant developments boosting the growth of the market. This report is prepared based on a detailed assessment of the industry by experts. To conclude, stakeholders, investors, product managers, marketing executives, and other experts in search of factual data on supply, demand, and future predictions would find the report valuable.

The report constitutes:Chapter 1 provides an overview of Nanotechnology in Medical market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Nanotechnology in Medical market by type, application, and region are also presented in this chapter.Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.Chapter 3 provides a full-scale analysis of major players in Nanotechnology in Medical industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.Chapter 4 gives a worldwide view of Nanotechnology in Medical market. It includes production, market share revenue, price, and the growth rate by type.Chapter 5 focuses on the application of Nanotechnology in Medical, by analyzing the consumption and its growth rate of each application.Chapter 6 is about production, consumption, export, and import of Nanotechnology in Medical in each region.Chapter 7 pays attention to the production, revenue, price and gross margin of Nanotechnology in Medical in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.Chapter 9 introduces the industrial chain of Nanotechnology in Medical. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.Chapter 10 provides clear insights into market dynamics.Chapter 11 prospects the whole Nanotechnology in Medical market, including the global production and revenue forecast, regional forecast. It also foresees the Nanotechnology in Medical market by type and application.Chapter 12 concludes the research findings and refines all the highlights of the study.Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:Historical Years: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Period: 2020-2025

About Us:Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.We are instrumental in providing quantitative and qualitative insights on your area of interest by bringing reports from various publishers at one place to save your time and money. A lot of organizations across the world are gaining profits and great benefits from information gained through reports sourced by us.

Contact us:Mr. Abhishek Paliwal5933 NE Win Sivers Drive, #205, Portland,OR 97220 United StatesDirect: +1-971-202-1575Toll Free: +1-800-910-6452E-mail:[emailprotected]

See more here:
Nanotechnology in Medical Market 2020 Explain What is the current size of the market? And key players analysis: Roche, Mitsui Chemicals, Camurus,...

Read More...

Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region – Good Night, Good Hockey

August 21st, 2020 11:59 am

Nanomedicine Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/39223

Nanomedicine is an application of nanotechnology, which are used in diagnosis, treatment, monitoring, and control of biological systems. Nanomedicine usages nanoscale manipulation of materials to improve medicine delivery. Therefore, nanomedicine has facilitated the treatment against various diseases. The nanomedicine market includes products that are nanoformulations of the existing drugs and new drugs or are nanobiomaterials. The research and development of new devices as well as the diagnostics will become, more effective, enabling faster response and the ability to treat new diseases are likely to boost the market growth.

The nanomedicine markets are driven by factors such as developing new technologies for drug delivery, increase acceptance of nanomedicine across varied applications, rise in government support and funding, the growing need for therapies that have fewer side effects and cost-effective. However, long approval process and risks associated with nanomedicine (environmental impacts) are hampering the market growth at the global level. An increase in the out-licensing of nanodrugs and growth of healthcare facilities in emerging economies are likely to create lucrative opportunities in the nanomedicine market.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Nanomedicine Market Segmentation Analysis:Based on the application, the nanomedicine market has been segmented into cardiovascular, neurology, anti-infective, anti-inflammatory, and oncology. The oncology segment held the dominant market share in 2018 and is projected to maintain its leading position throughout the forecast period owing to the rising availability of patient information and technological advancements. However, the cardiovascular and neurology segment is projected to grow at the highest CAGR of XX% during the forecast period due to presence of opportunities such as demand for specific therapeutic nanovectors, nanostructured stents, and implants for tissue regeneration.

Nanomedicine Market Regional Analysis:Geographically, the Nanomedicine market has been segmented into North America, the Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the Nanomedicine market in 2018 due to the rising presence of patented nanomedicine products, the availability of advanced healthcare infrastructure and the rapid acceptance of nanomedicine. The market in Asia Pacific is expected to expand at a high CAGR of XX% during the forecast period thanks to rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, the rising investments in research and development activities for the introduction of advanced therapies and drugs are predicted to accelerate the growth of this region in the near future.

Nanomedicine Market Competitive landscapeMajor Key players operating in this market are Abbott Laboratories, CombiMatrix Corporation, General Electric Company, Sigma-Tau Pharmaceuticals, Inc, and Johnson & Johnson. Manufacturers in the nanomedicine are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present a comprehensive analysis of Nanomedicine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market are presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Nanomedicine Market dynamics, structure by analyzing the market segments and project the Nanomedicine Market size. Clear representation of competitive analysis of key players By Type, Price, Financial position, Product portfolio, Growth strategies, and regional presence in the Nanomedicine Market make the report investors guide.Scope of the Nanomedicine Market:

Nanomedicine Market by Modality:

Diagnostics TreatmentsNanomedicine Market by Diseases:

Oncological Diseases Infectious Diseases Cardiovascular Diseases Orthopedic Disorders Neurological Diseases Urological Diseases Ophthalmological Diseases Immunological DiseasesNanomedicine Market by Application:

Neurology Cardiovascular Anti-Inflammatory Anti-Infectives OncologyNanomedicine Market by Region:

Asia Pacific North America Europe Latin America Middle East AfricaNanomedicine Market Major Players:

Abbott Laboratories CombiMatrix Corporation General Electric Company Sigma-Tau Pharmaceuticals, Inc Johnson & Johnson Mallinckrodt plc. Merck & Company, Inc. Nanosphere, Inc. Pfizer, Inc. Teva Pharmaceutical Industries Ltd. Celgene Corporation UCB (Union Chimique Belge) S.A. AMAG Pharmaceuticals Nanospectra Biosciences, Inc. Arrowhead Pharmaceuticals, Inc. Leadiant Biosciences, Inc. Epeius Biotechnologies Corporation Cytimmune Sciences, Inc.

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/nanomedicine-market/39223/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Read the original here:
Nanomedicine Market: Industry Analysis and forecast 2026: By Modality, Diseases, Application and Region - Good Night, Good Hockey

Read More...

New ‘molecular computers’ find the right cells – UW Medicine Newsroom

August 21st, 2020 11:59 am

Scientists have demonstrated a new way to precisely target cells by distinguishing them from neighboring cells that look quite similar.

Even cells that become cancerous may differ from their healthy neighbors in only a few subtle ways. A central challenge in the treatment of cancer and many other diseases is being able to spot the right cells while sparing all others.

In a paper published 20 August inScience FirstReleasea team of researchers at the University of Washington School of Medicine and theFred Hutchinson Cancer Research Centerin Seattle describe the design of new nanoscale devices made of synthetic proteins. These target a therapeutic agent only to cells with specific, predetermined combinations of cell surface markers.

Remarkably, these 'molecular computers' operate all on their own and can search out the cells that they were programmed to find.

"We were trying to solve a key problem in medicine, which is how to target specific cells in a complex environment," said Marc Lajoie, a lead author of the study and recent postdoctoral scholar at the UW MedicineInstitute for Protein Design. "Unfortunately, most cells lack a single surface marker that is unique to just them. So, to improve cell targeting, we created a way to direct almost any biological function to any cell by going after combinations of cell surface markers."

The tool they created is called Co-LOCKR, or Colocalization-dependant Latching Orthogonal Cage/Key pRoteins. It consists of multiple synthetic proteins that, when separated, do nothing. But when the pieces come together on the surface of a targeted cell, they change shape, thereby activating a sort of molecular beacon.

The presence of these beacons on a cell surface can guide a predetermined biological activity -- like cell killing -- to a specific, targeted cell.

The researchers demonstrated that Co-LOCKR can focus the cell-killing activity of CAR T cells. In the lab, they mixed Co-LOCKR proteins, CAR T cells, and a soup of potential target cells. Some of these had just one marker, others had two or three. Only the cells with the predetermined marker combination were killed by the T cells. If a cell also had a predetermined "healthy marker," then that cell was spared.

"T cells are extremely efficient killers, so the fact that we can limit their activity on cells with the wrong combination of antigens yet still rapidly eliminate cells with the correct combination is game-changing," said Alexander Salter, another lead author of the study and an M.D./Ph.D. student in the medical scientist program at the UW School of Medicine. He is training in Stanley Riddell's lab at the Fred Hutchinson Cancer Research Center.

This cell-targeting strategy relies entirely on proteins. This approach sets it apart from most other methods that rely on engineered cells and operate on slower timescales.

"We believe Co-LOCKR will be useful in many areas where precise cell targeting is needed, including immunotherapy and gene therapy," said David Baker, professor of biochemistry at the UW School of Medicine and director of the Institute for Protein Design.

Theresearch was conducted at the Institute for Protein Design, the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Research Center, and the UW Department of Bioengineering.

The co-lead authors of this work are Marc J. Lajoie (supported by a Washington Research Foundation Innovation Postdoctoral Fellowship and a Cancer Research Institute Irvington Fellowship from the Cancer Research Institute), Scott E. Boyken (supported by the Burroughs Wellcome Fund Career Award at the Scientific Interface), and Alexander I. Salter (supported by the Hearst Foundation and Fred Hutchinson Cancer Research Center Interdisciplinary Training Grant in Cancer Research).

This work was also supported by the National Institutes of Health, National Science Foundation, the Defense Threat Reduction Agency, Nordstrom Barrier Institute for Protein Design Directors Fund, Hearst Foundation, Washington Research Foundation and Translational Research Fund, Howard Hughes Medical Institute, Open Philanthropy Project, and The Audacious Project organized by TED.

Several authors are inventors on patents related to this work. Some hold equity in Lyell Immunopharma. Some authors are now employees or consultants of Lyell Immunopharma.

This news release was written by Ian Haydon of the Institute for Protein Design.

Read the original here:
New 'molecular computers' find the right cells - UW Medicine Newsroom

Read More...

Subaru Taps Xilinx For Its New EyeSight Vision-Based Advanced Driver-Assistance System – Forbes

August 21st, 2020 11:58 am

Xilinx Automotive-Qualified (XA) Zynq UltraScale+ Multi-Processor System-On-A-Chip (MPSoC)

Auto makers have been continually updating and augmenting their vehicle line-ups with new, leading-edge technologies as they lay the foundation for future, fully-autonomous vehicles. Though the field is advancing rapidly, were not quite there yet. Technologies being introduced today, however, inch us ever closer to that fully-autonomous future and enhance current vehicles with additional capabilities to improve safety, comfort, or both.

Such is the case with Subaru and its upcoming Levorg. Subaru just announced that it has partnered with Xilinx to enable the Levorg with a leading-edge, vision-based ADAS system (Advanced Driver Assistance System) using stereo cameras, dubbed EyeSight. Subarus EyeSight system will enable new features like adaptive cruise control, lane-keep assist and pre-collision braking to name just a few.

At Subaru, we continuously strive to make the Subaru brand prominent in our customers hearts and minds by focusing our efforts on providing Enjoyment and Peace of Mind, and we believe ADAS is one of the technologies that will help us achieve that goal, said Tetsuo Fujinuki, chief technology officer, Subaru Corporation. Stereo cameras are at the heart of Subarus ADAS applications. Unlike common approaches, the image processing technology adopted in our new generation system scans everything captured by stereo cameras and creates high-precision 3D point clouds, enabling us to offer advanced features such as pre-collision braking at an intersection and assisting with hands-off driving in traffic congestion on a highway. Xilinx technology plays an important role in this. Because Xilinx automotive devices contain built-in capabilities that allow us to meet strict ASIL requirements, they are unquestionably the best technology to implement Subarus new ADAS vision system.

The Automotive Safety Integrity Level, or ASIL, is a risk classification system defined by the ISO 26262 standard for the functional safety of road vehicles.

Xilinx ADAS And AD Features

Subarus EyeSight system is built around the Xilinx Automotive-qualified (XA) Zynq UltraScale+ multi-processor system-on-a-chip (MPSoC). The XA Zynq UltraScale+ is a 16-nanometer product that enables high-speed data aggregation, pre-processing, and distribution (DAPD), as well as compute acceleration for L2+ to L4 ADAS and autonomous driving (AD) applications. The XA Zynq UltraScale+ is capable of processing stereo images and data captured by the Subaru EyeSight systems cameras and sensors into 3D point clouds with the low latency, which are used to dynamically react to the environment.

Xilinx Zynq UltraScale+ High-Level Block Diagram.

We are excited to see Xilinx automotive devices enabling the new generation of automotive safety for Subaru, said Yousef Khalilollahi, vice president of sales, Asia-Pacific region, Xilinx. Subarus name has long been synonymous with road safety and reliability, and were proud that our XA products have been selected to continue our shared vision of providing drivers with the most advanced safety features on the market.

The Subaru Levorg, featuring the auto makers next-gen EyeSight ADAS system will be available for pre-orders in Japan starting tomorrow (August 20).

Read more from the original source:
Subaru Taps Xilinx For Its New EyeSight Vision-Based Advanced Driver-Assistance System - Forbes

Read More...

Leading sight organizations to merge in fight to end global crisis in vision – Chinadaily USA

August 21st, 2020 11:58 am

James Chen is seen with children working on his philanthropic cause to give everyone access to vision correction if they need it. Photo provided to China Daily

Clearly, the eyesight charity set up by Chinese philanthropist James Chen, is to merge with the International Agency for the Prevention of Blindness next year in a bid to increase efforts in supporting better vision globally.

Over the last 15 years, Chen had made it his mission to tackle poor vision. He has been funding and leading work to promote universal access to glasses and said the merger is a step closer to his dream of helping the whole world see clearly.

The International Agency for the Prevention of Blindness, or IAPB, is a network of more than 150 members working in international eye health and leading global advocacy body for the sight sector.

The new partnership, which will come into effect on Jan 1,2021, was created to combine the two organizations' advocacy and campaigning expertise as a way to renew pressure on governments and global leaders to end the vision crisis.

In a report published in October, the World Health Organization said it would cost an estimated $14.3 billion to treat the 1 billion people already living with visual impairment or blindness from cataracts, and short and far-sightedness.

Chen said: "IAPB have long been a leader in the vision sector. I am delighted that we will be able to combine their unprecedented authority and reach within the sector with our ground-breaking campaigning work, particularly on school eye health, work-based sight tests and the links between vision and delivery of the Sustainable Development Goals."

Along with his ongoing interests as founder of Vision for a Nation and Adlens, Chen will play an even more active role in the vision sector following the merger, as a global ambassador for IAPB.

Peter Holland, chief executive of the IAPB, said that the unprecedented move marks the "next exciting phase in the battle to deliver vision for everyone".

"This is a hugely important development for the sector and comes at a time when poor vision is rising across the world," Holland said. "Clearly has made massive strides forward in waking up the world to the scale of the vision crisis. This merger will provide the IAPB with renewed vigor and expertise in effective campaigning. It will enable us to make the case even more effectively about the urgency and value for money of tackling the global vision crisis."

Read the original post:
Leading sight organizations to merge in fight to end global crisis in vision - Chinadaily USA

Read More...

Foresight: Eye-Net Mobile and Global Japanese Technology Company to Start Pilot Project – Business Wire

August 21st, 2020 11:58 am

NESS ZIONA, Israel--(BUSINESS WIRE)--Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today that its wholly owned subsidiary, Eye-Net Mobile Ltd., will start a pilot project with a multi-billion dollar global Japanese technology company to test its Eye-Net Protect cellular-based V2X (vehicle-to-everything) accident prevention solution.

The pilot project will be used to validate the Eye-Net solution capabilities and its technical specifications. Upon successful completion, the Japanese technology company may proceed to commercial integration of the Eye-Net solution into its IoT platform which currently serves millions of users.

This pilot project marks an important milestone on Eye-Net Mobiles commercial roadmap. The technology company will be the first to evaluate the software development kit (SDK) configuration of Eye-Net Protect. Integration with a global Japanese company has the potential to allow our life-saving accident prevention solution to protect millions of users daily, said Dror Elbaz, COO & Deputy CEO of Eye-Net Mobile.

The Eye-Net Protect V2X solution is designed to protect the most vulnerable road users in real time - including pedestrians, cyclists, scooter drivers and car drivers - by providing collision alerts when the road users have no direct line of sight. An SDK configuration allows Eye-Net Mobile to integrate its solution with leading location-based products such as wearable devices, dashboard cameras, navigation aids, infotainment systems, third-party applications and other smart devices.

For more information about Eye-Net Mobile, please visit http://www.eyenet-mobile.com, or follow the Companys LinkedIn page, Eye-Net Mobile; Twitter, @EyeNetMobile1; and Instagram channel, Eyenetmobile1, the contents of which are not incorporated into this press release.

About ForesightForesight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), founded in 2015, is a technology company engaged in the design, development and commercialization of sensors systems for the automotive industry. Through the companys wholly owned subsidiaries, Foresight Automotive Ltd. and Eye-Net Mobile Ltd., Foresight develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications. Foresights vision sensor is a four-camera system based on 3D video analysis, advanced algorithms for image processing, and sensor fusion. Eye-Net Mobiles cellular-based application is a V2X (vehicle-to-everything) accident prevention solution based on real-time spatial analysis of clients movement.

The companys systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is targeting the Advanced Driver Assistance Systems (ADAS), the semi-autonomous and autonomous vehicle markets and predicts that its systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform and advanced technology.

For more information about Foresight and its wholly owned subsidiary, Foresight Automotive, visit http://www.foresightauto.com, follow @ForesightAuto1 on Twitter, or join Foresight Automotive on LinkedIn.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Foresight is using forward-looking statements in this press release when it discusses the terms of any agreement between Eye-Net and the global Japanese technology company, that the pilot project will be used to validate the Eye-Net solution capabilities and its technical specifications, that upon successful completion, the Japanese technology company may proceed to commercial integration of the Eye-Net solution into its IoT platform, and that potential integration with a global Japanese company has the potential to protect millions of users daily. Because such statements deal with future events and are based on Foresights current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Foresight could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Foresight's annual report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 31, 2020, and in any subsequent filings with the SEC. Except as otherwise required by law, Foresight undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Foresight is not responsible for the contents of third party websites.

Read this article:
Foresight: Eye-Net Mobile and Global Japanese Technology Company to Start Pilot Project - Business Wire

Read More...

Cheri McDaniel is almost 92, but that’s not slowing her down one bit – The Advocate

August 21st, 2020 11:58 am

Nearing 92, Cheri McDaniel is losing her eyesight. But her vision for new ideas is going strong.

Early this year, McDaniel finished her third book, and she says a fourth one might be on the way. On the West Feliciana Parish property where she is riding out the coronavirus pandemic with family members, she is creating plans for the gardens, ponds and structures she has built over the past five decades.

She also continues to raise money for charity work in Haiti and Swaziland through Rotary an organization she joined while creating a medical and educational mission in Mexico. She was only 75 then.

This likely surprises no one who knows McDaniel, who also has been a house designer, builder and antique store owner.

"I think her energy comes from her passions, either her passion to write, her passion to help others, her passion to serve," said Martha Stuckey, president of theCapital City Rotary Club, of which McDaniel is a member.

McDaniel suggests she doesnt deserve much credit.

Im a simple farm girl, she said. I feel that God is driving the vehicle of my life or I wouldnt still be here. These things just evolve.

Its been that way since McDaniel, who was born in 1928, grew up on a Union Parish farm through the Great Depression, earned a home economics degree and became a hospital dietitian. She met her first husband, Jack Smith, at LSU, and his oil industry work took them to El Dorado, Arkansas, and Memphis, Tennessee, before coming to Baton Rouge in 1947.

In each location, McDaniel designed the couple's home. Despite no formal education in construction or architecture, she discovered she had the ability to visualize a house and taught herself how to draw up plans that carpenters and other tradesmen could follow.

In Baton Rouge, she was a homemaker until their only child, Susan, was old enough to go to school. Since being a dietitian no longer appealed to her, she told Jack in 1958 that she was going to design and build homes for a living. She says she was the only woman to run such a company in Baton Rouge at the time and designed about 200 homes in 27 years.

I never did two houses alike, McDaniel said. Id meet with them, find out what they really wanted to have in a house, what was their budget, and it was my goal to be able to give them everything they wanted, and most of the time I was able to do that within their budget. And they left me alone.

Along the way, she founded Fireside Antiques in 1982, which Susan managed until becoming pregnant with quadruplets in 1986, so McDaniel took over and ran the business until 2003.

When she was in her mid-70s, sensing that God was calling her to the mission field, she moved to San Miguel de Allende, Mexico, and started the Holistic Educational Center, a facility that provided both medical care and education to improve the lives of impoverished residents there. She wrote grant applications that helped fund a retinopathy clinic at the local hospital there.

However, after four years, the 6,000-foot altitude was causing McDaniel fainting spells, and her second marriage was ending, so she returned to Baton Rouge. She joined the Capital City Rotary Club upon her return, writing grant proposals that created funding for outreach projects.

McDaniel moved to St. James Place retirement community. That's where she got the inspiration to write.

It began with her life story, titled He Lays the Stones for Our Steps, which she followed with Snazzy Seniors, telling stories of interesting and inspirational people she met. She sells the books through her Rotary club, and its proceeds go to club projects.

In her third book, Descending Toward Darkness, Illuminated by Faith, she tells the stories of people shes met who have come through challenges. God, she said, gave her the title. It was printed just before St. James Place went into lockdown in March, which McDaniel believes is no coincidence.

God had to have known that this pandemic was coming to give me such a strange title, she said. I wasnt planning to write a third book. I had never studied creative writing. So, God is still keeping me going.

The title also reflects some of McDaniels own experience.

A cancer survivor, she has faced numerous recent health challenges: congestive heart failure, shingles, knee surgery and failing eyesight that forced her to hand-write passages of the book in large letters so someone else could type them. She continues to write, currently focusing on spiritual topics.

I am now legally blind, but nothing seems to stop our heavenly father, she said. My writing has become a wonderful adventure.

One of many.

Every morning after breakfast, an assistant drives her in a golf cart for two hours to look over 388 acres near Lake Rosemound where McDaniel has built houses for family members and created a forest and garden from what was once a cow pasture.

McDaniel once held Easter sunrise worship services on the property and wanted to build a church there, but when the family didnt agree due to lack of suitable parking space, she built a small, open-air meditation chapel. Hundreds of encore azaleas bloom multiple times a year, creating vibrant color even in the August heat.

Its like I feel reborn in this environment, McDaniel said. Im still alive, and Im still being inspired by the infinite creator. I take no credit. His presence is so strong.

Read more here:
Cheri McDaniel is almost 92, but that's not slowing her down one bit - The Advocate

Read More...

Page 410«..1020..409410411412..420430..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick